Ixazomib, a drug of multiple myeloma in Takeda, is qualified as a breakthrough drug of FDA

Source: Ding Xiangyuan on December 3, 2014, Takeda and its new president, Weber, recently released some encouraging news with the continuous decline of final profits and the approaching of large-scale budget cuts The FDA has awarded ixazomib (mln9708), a breakthrough drug for multiple myeloma, which is in the critical later stage of research This drug aims to become the successor of the blockbuster bortezomib FDA grants breakthrough drug qualification based on the company's work on systemic light chain (AL) amyloidosis AL amyloidosis is related to multiple myeloma Amyloid protein accumulation will occur in patients with multiple myeloma and damage human organs Takeda is the fastest advancing project in the clinical trials of amyloidosis It has jumped directly from phase 1 to phase 3, but prothena, an Irish biotechnology company, has a drug that is in the early stage of development and is used for the same disease According to Takeda, AL amyloidosis is a rare, aggressive protein structural misfolding disease, which is diagnosed in less than 3000 patients in the United States every year Takeda has achieved some success in recent years, the most important is the approval of the inflammatory bowel disease treatment drug vedolizumab But the company's late stage cancer competitor, tak-875 (fasiglifam), and its Cambridge, Ma, subsidiary, millennium, failed These setbacks prompted the company to cut its $1 billion forecast and lay off thousands of employees "This breakthrough treatment drug qualification is also an important recognition of our cancer development project advantages and our commitment to extend proteasome inhibitors to areas that have not been the focus of traditional research and development," vasoncelles, who is in charge of the cancer treatment unit in Takeda, said in a statement "We would like to thank patients, researchers and the organizations involved in the project for making this milestone possible."